<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662411</url>
  </required_header>
  <id_info>
    <org_study_id>NL75253.068.20</org_study_id>
    <nct_id>NCT04662411</nct_id>
  </id_info>
  <brief_title>Butyrate/Hexanoate in Metabolic Health</brief_title>
  <official_title>Butyrate/Hexanoate-enriched Triglycerides for Metabolic Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we aim to identify a well consumable butyrate/hexanoate-enriched oil that&#xD;
      increases circulating SCFA concentrations and improves postprandial substrate metabolism,&#xD;
      which could be further used for a long-term study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma butyrate concentrations</measure>
    <time_frame>Fasting and postprandial butyrate will be measured before and up to 6 hours after intake of the supplement</time_frame>
    <description>Plasma butyrate concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating Glucose</measure>
    <time_frame>Fasting and postprandial glucose will be measured before and up to 6 hours after intake of the supplement</time_frame>
    <description>Circulating Glucose assessed in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Free Fatty Acids</measure>
    <time_frame>Fasting and postprandial Free Fatty Acids will be measured before and up to 6 hours after intake of the supplement</time_frame>
    <description>Circulating Free Fatty Acids assessed in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Glycerol</measure>
    <time_frame>Fasting and postprandial Glycerol will be measured before and up to 6 hours after intake of the supplement</time_frame>
    <description>Circulating Glycerol assessed in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Triglycerides (TG)</measure>
    <time_frame>Fasting and postprandial TG will be measured before and up to 6 hours after intake of the supplement</time_frame>
    <description>Circulating Triglycerides assessed in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating insulin</measure>
    <time_frame>Fasting and postprandial insulin will be measured before and up to 6 hours after intake of the supplement</time_frame>
    <description>Circulating . insulin will be assessed in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath H2</measure>
    <time_frame>Fasting and postprandial breath H2 will be measured before and up to 6 hours after intake of the supplement</time_frame>
    <description>Breath H2 using Gastrolyzer</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Metabolic Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>butyrate and hexanoate amount 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1325 mg of butyrate and hexanoate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>butyrate and hexanoate amount 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>butyrate and hexanoate amount 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>acute intake of 0 mg butyrate and hexanoate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>butyrate and hexanoate amount 1</intervention_name>
    <description>acute intake of 650 mg butyrate and hexanoate</description>
    <arm_group_label>butyrate and hexanoate amount 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>butyrate and hexanoate amount 2</intervention_name>
    <description>acute intake of 1325 mg butyrate and hexanoate</description>
    <arm_group_label>butyrate and hexanoate amount 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>butyrate and hexanoate amount 3</intervention_name>
    <description>acute intake of 2000 mg butyrate and hexanoate</description>
    <arm_group_label>butyrate and hexanoate amount 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Overweight/obese men (BMI ≥ 25 kg/m2 and ≤ 34.9 kg/m2);&#xD;
&#xD;
          -  Aged 40 - 70 years;&#xD;
&#xD;
          -  Caucasian;&#xD;
&#xD;
          -  Normal blood pressure (systolic blood pressure 100-140mmHg, diastolic blood pressure&#xD;
             60-90 mmHg);&#xD;
&#xD;
          -  Weight stable for at least 3 months (± 2 kg).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Type 2 diabetes mellitus (defined as fasting plasma glucose ≥ 7.1 mmol/L)&#xD;
&#xD;
          -  Gastroenterological diseases or abdominal surgery (gallbladder removal and appendix&#xD;
             removal are allowed)&#xD;
&#xD;
          -  Cardiovascular diseases, cancer, liver or kidney malfunction, disease with a life&#xD;
             expectancy shorter than 5 years;&#xD;
&#xD;
          -  Lactose intolerance or other disorders that affect digestion (such as celiac disease)&#xD;
&#xD;
          -  Abuse of products; alcohol and drugs, excessive nicotine use defined as &gt;20 cigarettes&#xD;
             per day; and excessive alcohol use defined as (&gt; 15 units/week)&#xD;
&#xD;
          -  Plans to lose weight or following of a hypocaloric diet in the following three months;&#xD;
&#xD;
          -  Regular supplementation of pre- or probiotic products (for example Yakult, Activia),&#xD;
             use of pre- or probiotics 3 months prior to the start of the study;&#xD;
&#xD;
          -  Intensive exercise training more than three hours a week;&#xD;
&#xD;
          -  Use of any medication that influences glucose or fat metabolism and inflammation (i.e.&#xD;
             betablockers, corticosteroids, statins or NSAIDs);&#xD;
&#xD;
          -  Regular use of laxation products in 3 months prior start of study or during study&#xD;
             period;&#xD;
&#xD;
          -  Use of antibiotics in the last three months (antibiotics use can alter substantially&#xD;
             the gut microbiota composition).&#xD;
&#xD;
          -  Follow a vegan diet or vegetarian diet.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emanuel Canfora, PhD</last_name>
    <phone>+31-43 38 81669</phone>
    <email>emanuel.canfora@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuel E Canfora, PhD</last_name>
      <phone>+31 43 3881 669</phone>
      <email>emanuel.canfora@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

